Scarica l'app Stockscreener
2.98
0.33%
-0.01
Dopo l'orario di chiusura:
3.00
0.02
+0.67%
Prime Medicine Inc Borsa (PRME) Ultime notizie
Bank of America Corp DE Makes New $3.62 Million Investment in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Up 6.1%Still a Buy? - MarketBeat
Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency - AllSci
Citizens reiterates Prime Medicine stock rating on gene editing capabilities By Investing.com - Investing.com Canada
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
PRME Stock Dips As Prime Medicine Faces Steep Losses - StocksToTrade
Prime Medicine Stock Slips As Traders Digest Weak Margins - StocksToTrade
Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME) - Seeking Alpha
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Prime Medicine Gets FDA Green Light for Gene Editing Study - Benzinga
Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer Says - marketscreener.com
Prime Medicine (NASDAQ:PRME) Shares Gap UpWhat's Next? - MarketBeat
FDA Clears Prime Medicine to Start Gene Editing Trial After Beam Dispute - GenomeWeb
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore
Prime Medicine’s PM-647 gains IND approval for AATD - BioWorld News
Prime Medicine (NASDAQ:PRME) Earns Buy Rating from Chardan Capital - MarketBeat
Prime Medicine stock holds at outperform on FDA IND clearance By Investing.com - Investing.com Australia
Prime Medicine stock holds at outperform on FDA IND clearance - Investing.com
Prime Medicine stock jumps 8% after FDA clears PM647 trial - TradingView
TD Cowen Maintains Prime Medicine(PRME.US) With Buy Rating - Moomoo
Prime Medicine keeps Buy rating with key clinical milestones and potential 2027 BLA for CGD. - Pluang
Chardan Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Stocks to Watch: Akamai, Scholastic, Prime Medicine - Moomoo
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm647 In Alpha-1 Antitrypsin Deficiency - TradingView
Why is Prime Medicine stock surging today? By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Prime Medicine stock surges on FDA IND clearance By Investing.com - Investing.com Australia
Prime Medicine stock surges on FDA IND clearance - Yahoo Finance
Prime Medicine receives FDA clearance for AATD gene therapy - Investing.com
Prime Medicine receives FDA clearance for AATD gene therapy By Investing.com - Investing.com South Africa
FDA clears testing of a genetic treatment aimed at a variant carried by about 100,000 people in the U.S. - Stock Titan
Prime Medicine (PRME) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.5%Should You Sell? - MarketBeat
Can Prime Medicine (NASDAQ:PRME) Afford To Invest In Growth? - Moomoo
Prime Medicine, Inc. (NASDAQ:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine (NASDAQ:PRME): What's Behind Its Sudden Share Price Jump? - Kalkine Media
Prime Medicine (NASDAQ:PRME) Shares Up 11.8%Should You Buy? - MarketBeat
PRME: Prime Editing advances versatile gene therapies with strong clinical and financial momentum - TradingView
Prime Medicine at H.C. Wainwright conference: platform gains focus By Investing.com - Investing.com Canada
Prime Medicine (NASDAQ:PRME) Rating Increased to Hold at Wall Street Zen - MarketBeat
Prime Medicine (NASDAQ:PRME) Stock Price Down 4.3%Here's What Happened - MarketBeat
A gene-editing company sets three September conference appearances - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - Yahoo Finance
BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital - marketbeat.com
ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Up 6.3%Here's What Happened - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 6.9%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
Prime Medicine Company Profile & Introduction - Moomoo
PRIME MEDICINE, INC. : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $9 - Bitget
PRME Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Prime (PRME) Results Breakdown: The Available Earnings Metric Delivers a Beat for the Current Session; Investor Response: Shares Fall 3.79% on the DayConsensus Beat Rate - vinanet.vn
BMO initiates Prime Medicine stock with outperform rating By Investing.com - Investing.com Canada
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):